These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 36508915)
1. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China. Deng M; Su Y; Wu R; Li S; Tang G; Kuang Q; Luo X; Zhu Y; Shen W Int Immunopharmacol; 2023 Jan; 114():109530. PubMed ID: 36508915 [TBL] [Abstract][Full Text] [Related]
2. Severe cutaneous adverse reactions: A 5-year retrospective study at Hospital Melaka, Malaysia, from December 2014 to February 2020. Tee CT; Abdullah NH; Kristummoonthy P; Lee CS Med J Malaysia; 2022 Jul; 77(4):409-414. PubMed ID: 35902928 [TBL] [Abstract][Full Text] [Related]
3. A retrospective, 5-year, clinicoepidemiological study of severe cutaneous adverse reactions (SCARs). Singh GK; Mitra B; Arora S; Akhoon N; Verma R; Sharma P; Mitra D Int J Dermatol; 2021 May; 60(5):579-588. PubMed ID: 33454956 [TBL] [Abstract][Full Text] [Related]
4. Antibiotic-induced severe cutaneous adverse reactions: a single-center retrospective study over ten years. Lu Y; Zhou L; Zou Y; Wei H; Zhou Y; Guo X; Li Q; Ye Y; Zhang L Front Immunol; 2024; 15():1415830. PubMed ID: 39091503 [TBL] [Abstract][Full Text] [Related]
5. Severe Cutaneous Adverse Reactions: A Single-Center Retrospective Study of 173 Patients in China. Xu Z; Shen J; Yang Y; Yuan R; Xiang LF; Zhang C Ann Dermatol; 2019 Oct; 31(5):545-554. PubMed ID: 33911647 [TBL] [Abstract][Full Text] [Related]
6. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis). Owen CE; Jones JM Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239 [TBL] [Abstract][Full Text] [Related]
7. [The major SCAR syndromes]. Piérard GE; Lesuisse M; Piérard-Franchimont C Rev Med Liege; 2017 Oct; 72(10):444-447. PubMed ID: 29058836 [TBL] [Abstract][Full Text] [Related]
8. Key factors predicting the in-hospital mortality of patients with severe cutaneous adverse reactions in Thailand. Chuenboonngarm N; Puaratanaarunkon T; Washrawirul C; Triwatcharikorn J; Chancheewa B; Theerawattanawit C; Chongpison Y; Rerknimitr P; Klaewsongkram J J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1881-1890. PubMed ID: 37212641 [TBL] [Abstract][Full Text] [Related]
9. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J; Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927 [TBL] [Abstract][Full Text] [Related]
10. Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature. van Hattem S; Beerthuizen GI; Kardaun SH Br J Dermatol; 2014 Dec; 171(6):1539-45. PubMed ID: 24888401 [TBL] [Abstract][Full Text] [Related]
11. Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting. Liccioli G; Mori F; Parronchi P; Capone M; Fili L; Barni S; Sarti L; Giovannini M; Resti M; Novembre EM Clin Exp Allergy; 2020 Jan; 50(1):61-73. PubMed ID: 31608511 [TBL] [Abstract][Full Text] [Related]
12. Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs). Torres-Navarro I; de Unamuno-Bustos B; Botella-Estrada R J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):607-614. PubMed ID: 32846030 [TBL] [Abstract][Full Text] [Related]
13. Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan. Huang YS; Wu CY; Chang TT; Peng CY; Lo GH; Hsu CW; Hu CT; Huang YH Liver Int; 2021 Nov; 41(11):2671-2680. PubMed ID: 34153177 [TBL] [Abstract][Full Text] [Related]
14. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System. Godfrey H; Jedlowski P; Thiede R Australas J Dermatol; 2024 May; 65(3):243-253. PubMed ID: 38572842 [TBL] [Abstract][Full Text] [Related]
15. Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study. Dibek Misirlioglu E; Guvenir H; Bahceci S; Haktanir Abul M; Can D; Usta Guc BE; Erkocoğlu M; Toyran M; Nacaroglu HT; Civelek E; Buyuktiryaki B; Ginis T; Orhan F; Kocabas CN J Allergy Clin Immunol Pract; 2017; 5(3):757-763. PubMed ID: 28351788 [TBL] [Abstract][Full Text] [Related]
16. An observational study of severe cutaneous adverse reactions at a tertiary care teaching hospital. Lekshmipriya K; Pradeesh A; Vasudevan B; Dash M; Sood A; Gera V Med J Armed Forces India; 2023 Dec; 79(Suppl 1):S209-S216. PubMed ID: 38144617 [TBL] [Abstract][Full Text] [Related]
17. Severe cutaneous adverse reactions related to systemic antibiotics. Lin YF; Yang CH; Sindy H; Lin JY; Rosaline Hui CY; Tsai YC; Wu TS; Huang CT; Kao KC; Hu HC; Chiu CH; Hung SI; Chung WH Clin Infect Dis; 2014 May; 58(10):1377-85. PubMed ID: 24599767 [TBL] [Abstract][Full Text] [Related]